Catalyst Pharmaceutical Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for CPRX, updated each market day.
CPRX AI Sentiment
AI sees no strong directional signal for Catalyst Pharmaceutical Inc. stock over the next 10 market days.
Prediction date: May 20, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Catalyst Pharmaceutical Inc.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
Sector
Exchange
Market Cap
$3,813,391,710
Cap Tier
Employees
182
Headquarters
CORAL GABLES, FL
Listed Since
Nov. 8, 2006
Website
CPRX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
CPRX Volatility
Catalyst Pharmaceutical Inc. has shown low price volatility over the last 5 trading days. Low volatility suggests steady price action with smaller daily moves.
